BIOMAT Database Logo BIOMAT Database Logo

Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC). 1998

P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Divisione di Oncologia Medica, IRCCS Fondazione Salvatore Maugeri, Clinica del Lavoro e della Riabilitazione, Pavia, Italy.

We have evaluated the combination of ifosfamide, carboplatin and etoposide (ICE regimen) along with mesna in 26 previously untreated patients with non small cell lung cancer (NSCLC). Thirteen stage III B and 13 stage IV patients received intermediate doses of ifosfamide (1000 mg/m2), carboplatin (120 mg/m2) and etoposide (120 mg/m2) given intravenously on day 1 to 3 every 4 weeks. Except for one patient who experienced grade 3 transient thrombocytopenia no major events of hematological or systemic toxicity were observed. Response rate (27%, 95% C.I., 10 to 44%), median duration of response (9 months, range 6-15), and survival (9.5 months, range 2-44+) were comparable to those achieved with conventional cisplatin-containing regimens. Our ICE combination, as compared to standard or high dose schedules appears effective, safe, well tolerated, and devoid of severe hematological toxicity.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC).
August 2001, Journal of chemotherapy (Florence, Italy),
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
December 1994, American journal of clinical oncology,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer.
August 1998, Lung cancer (Amsterdam, Netherlands),
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
April 2002, Ai zheng = Aizheng = Chinese journal of cancer,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
May 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
February 1992, Seminars in oncology,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.
May 2003, Annals of oncology : official journal of the European Society for Medical Oncology,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Oral etoposide preceding cisplatin in advanced non small cell lung cancer (NSCLC). A phase II study.
September 1988, European journal of cancer & clinical oncology,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.
December 1992, Seminars in oncology,
P Preti, and G Poggi, and A M Cuomo, and F S Robustelli della Cuna, and A Zambelli, and L Pavesi
A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
January 2005, Oncology,
Copied contents to your clipboard!